Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells

被引：0
|
作者：
Sun, Baohua
Fiskus, Warren
Raina, Kanak
Qian, Yimin
Crew, Andrew
Saenz, Dyana T.
Mill, Christopher Peter
Nowak, Agnieszka J.
Saenz, David N.
Crews, Craig M.
Bhalla, Kapil N.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1265
引用
收藏
页数：2
相关论文
共 10 条
  • [1] Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs)Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells
    Sun, Baohua
    Fiskus, Warren
    Zhang, Liang
    Raina, Kanak
    Coleman, Kevin
    Winkler, Jim
    Qian, Yimin
    Crew, Andrew
    Shen, Angela
    Saenz, Dyana T.
    Mill, Christopher P.
    Wang, Michael
    Crews, Craig
    Bhalla, Kapil N.
    BLOOD, 2016, 128 (22)
  • [2] Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells
    Saenz, Dyana T.
    Fiskus, Warren
    Raina, Kanak
    Manshouri, Taghi
    Coleman, Kevin
    Winkler, Jim
    Qian, Yimin
    Crew, Andrew
    Shen, Angela
    Mill, Christopher P.
    Sun, Baohua
    Verstovsek, Srdan
    Crews, Craig
    Bhalla, Kapil N.
    BLOOD, 2016, 128 (22)
  • [3] BET protein proteolysis targeting chimera (BETP-PROTACs) exert more potent activity than BETP bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
    Saenz, Dyana T.
    Fiskus, Warren C.
    Raina, Kanak
    Manshouri, Taghi
    Coleman, Kevin G.
    Qian, Yimin
    Crew, Andrew P.
    Shen, Angela
    Mill, Christopher P.
    Sun, Baohua
    Kim, Misun
    Nowak, Agnieszka J.
    Verstovsek, Srdan
    Crews, Craig M.
    Bhalla, Kapil N.
    CANCER RESEARCH, 2017, 77
  • [4] BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Exert Potent Activity Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s)-AML Cells
    Saenz, Dyana
    Fiskus, Warren
    Manshouri, Taghi
    Mill, Christopher
    Sun, Baohua
    Verstovsek, Srdan
    Bhalla, Kapil
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S358 - S358
  • [5] BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
    Sun, B.
    Fiskus, W.
    Qian, Y.
    Rajapakshe, K.
    Raina, K.
    Coleman, K. G.
    Crew, A. P.
    Shen, A.
    Saenz, D. T.
    Mill, C. P.
    Nowak, A. J.
    Jain, N.
    Zhang, L.
    Wang, M.
    Khoury, J. D.
    Coarfa, C.
    Crews, C. M.
    Bhalla, K. N.
    LEUKEMIA, 2018, 32 (02) : 343 - 352
  • [6] BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
    B Sun
    W Fiskus
    Y Qian
    K Rajapakshe
    K Raina
    K G Coleman
    A P Crew
    A Shen
    D T Saenz
    C P Mill
    A J Nowak
    N Jain
    L Zhang
    M Wang
    J D Khoury
    C Coarfa
    C M Crews
    K N Bhalla
    Leukemia, 2018, 32 : 343 - 352
  • [7] Cyclin D1 Driven CDK4 Activity Is Responsible for Hypersensitivity to NOXA Inducing Combination Treatment in Mantle Cell Lymphoma (MCL) Cells
    Heine, Simon
    Silkenstedt, Elisabeth
    Dengler, Michael A.
    Markus, Kleih
    Ott, German
    Carabaza, Neus Gimenez
    Dolors, Colomer
    van der Kuip, Heiko
    Aulitzky, Walter E.
    BLOOD, 2017, 130
  • [8] Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells
    Sun, Baohua
    Fiskus, Warren
    Shah, Bhavin
    Qi, Jun
    Devaraj, Santhana G. T.
    Iyer, Swaminathan Padmanabhan
    Sharma, Sunil
    Bradner, James
    Zu, Youli
    Bhalla, Kapil N.
    BLOOD, 2014, 124 (21)
  • [9] BET Protein Bromodomain Antagonist-Based Combinations Exert Synergistic Pre-Clinical Activity Against Ibrutinib-Sensitive or -Resistant Human Mantle Cell Lymphoma (MCL) Cells
    Sun, Baohua
    Fiskus, Warren
    Saenz, Dyana T.
    Krieger, Stephanie
    Zhang, Liang
    Parmar, Simrit
    Wang, Michael
    Bhalla, Kapil N.
    BLOOD, 2015, 126 (23)
  • [10] Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat A highly active combination against human mantle cell lymphoma (MCL) cells
    Rao, Rekha
    Lee, Pearl
    Fiskus, Warren
    Yang, Yonghua
    Joshi, Rajeshree
    Wang, Yongchao
    Buckley, Kate
    Balusu, Ramesh
    Chen, Jianguang
    Koul, Sanjay
    Joshi, Atul
    Upadhyay, Sunil
    Tao, Jianguo
    Sotomayor, Eduardo
    Bhalla, Kapil N.
    CANCER BIOLOGY & THERAPY, 2009, 8 (13) : 1273 - 1280
1